DE Burlo Group Inc. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 19.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,350 shares of the company’s stock after selling 5,300 shares during the period. DE Burlo Group Inc.’s holdings in Neurocrine Biosciences were worth $1,028,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Neurocrine Biosciences by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,735,965 shares of the company’s stock valued at $291,666,000 after buying an additional 293,755 shares during the last quarter. BlackRock Inc. raised its position in Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares during the last quarter. Janus Capital Management LLC raised its position in Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares during the last quarter. Perceptive Advisors LLC raised its position in Neurocrine Biosciences by 1.5% in the first quarter. Perceptive Advisors LLC now owns 3,366,530 shares of the company’s stock valued at $145,771,000 after buying an additional 50,007 shares during the last quarter. Finally, BB Biotech AG raised its position in Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock valued at $138,627,000 after buying an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 95.87% of the company’s stock.

Shares of Neurocrine Biosciences, Inc. (NBIX) opened at 53.12 on Friday. The stock’s market capitalization is $4.69 billion. The firm’s 50-day moving average is $49.32 and its 200-day moving average is $47.18. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $55.38.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same period last year, the business posted ($0.46) EPS. Analysts forecast that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/18/de-burlo-group-inc-sells-5300-shares-of-neurocrine-biosciences-inc-nbix.html.

NBIX has been the subject of several recent research reports. Bank of America Corporation initiated coverage on shares of Neurocrine Biosciences in a report on Friday, May 5th. They set a “buy” rating and a $70.00 target price for the company. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Leerink Swann lowered their target price on shares of Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, May 25th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $75.00 target price on shares of Neurocrine Biosciences in a report on Thursday, May 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $68.25.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 10,000 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $53.39, for a total value of $533,900.00. Following the completion of the transaction, the insider now owns 107,691 shares of the company’s stock, valued at $5,749,622.49. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Haig P. Bozigian sold 22,500 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the insider now directly owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,588 shares of company stock valued at $2,940,070. 4.80% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.